An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life

Inclusion criteria

• Signed and dated informed consent obtained prior to any study related activities
• Aged 18 years or above
• Either sex
• Any race or ethnicity
• Attending a hospital outpatient clinic or the private practice of a board-certified dermatologist, dermatology-certified nurse practitioner or physician assistant trained in dermatology
• Clinical diagnosis of psoriasis vulgaris involving scalp and/or body amenable to treatment with a maximum of 100 g of topical medication per week.
• Patients who receive a prescription of calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension 0.005% / 0.064% as per an investigator's clinical judgment and in accordance with the US label, and who have access to the medication
• Able to communicate with the investigator, read and understand English, and understand and comply with the requirements of the study

Exclusion criteria

• Prior treatment with calcipotriene/betamethasone dipropionate (Taclonex®) topical suspension, 0.005%/0.064%.
• Contraindications or any warnings/precautions according to the US label.
• Current participation in any other interventional clinical study.
• Females who are pregnant, breast-feeding, or females of child-bearing potential wishing to become pregnant during the study.